Just wrapped an incredible journey as part of the Program Development Committee for NY Valves with @gu_asc1 @philippvstein @JennifervStein! 🚀. Innovation, insight and inspiration - #NYValves2025 delivered. Until next time! 🔧🫀 #NYValves @crfheart

RT @azeemlatib: Great cases and presentations from the @MonteHeart team. @EdwinHoMD @AndreaScotti21 @leoneppmd @UlrichJordeMD @m_assafin….

RT @CircIntv: Do female patients respond differently than males? Higher 2-year MACE after sirolimus-coated balloon angioplasty for female p….

RT @azeemlatib: Looking forward to seeing you at NY Valves!.

RT @ignamatsant: Ever wanted to learn the most complex interventional techniques without risk for your patients?.Then TACIT MEETING is for….

RT @UlrichJordeMD: 📢 Excited to welcome you to our #MonteHeart2025 Symposium @MontefioreNYC on June 12–13! . Scan QR or tap 🔗 in comments t….

RT @UlrichJordeMD: What’s next in HF, amyloid, HCM, valvular therapies, shock, and next-gen LVADs? 🤔. 🎓 Join #MonteHeart2025 to hear from a….

Let the #JOURNEY begin! 🚀. We are thrilled to announce our first #TAVR case at @MonteHeart as part of the JOURNEY pivotal study - a major step in pushing boundaries for #AR care. A shoutout to our incredible Team for making this possible @azeemlatib @EdwinHoMD

Great opportunity today sharing the floor with @azeemlatib @MonteHeart for an exciting update on #DCB #PCI . Stay tuned for the sequel “How do I use DCB?” at the next @MonteHeart conference!

Treatment of multilayer #ISR remains an unmet clinical need. Studies on #DCB in multilayer ISR are few, and further research is needed. These long-term findings on #DES ISR can serve as benchmark, and support development of future clinical trials @RichCardioMD @DhulipalaMD.

👩🏼‍🤝‍👨🏻Do clinical outcomes differ between females and males after sirolimus-coated balloon angioplasty #PCI?. Our analysis @CircIntv on >2000 patients in EASTBOURNE suggests so, particularly in ISR. #DCB .@BernardCortese @DrLucaTesta @AGrecoMD. 🔗

RT @jtorrado_arrosa: Severe TR in a Patient With a CIED: What We Have Learned | JACC: Case Reports.@azeemlatib⁩ ⁦@jcecharte⁩ ⁦⁦@MatteoSturl….

Fantastic @MonteHeart conference today with @sjorge4 live from Valencia 🇪🇸 . Great discussion on key coronary guidewire concepts, bench testing and clinical applications with @azeemlatib @lvjulien_md @m_assafin @MonteHeart . Thanks again and see you soon!.

RT @JAMACardio: This narrative review discusses drug-coated balloon angioplasty as an alternative to drug-eluting stent for percutaneous co….

SIBLINT-ISR RCT, the largest in DES ISR, showed noninferiority in in-segment late lumen loss at 9 months for sirolimus- vs. paclitaxel-coated balloons @JACCJournals . Feel free to read our thoughts @Antocol17 .🔗 Main: 🔗 Editorial:

RT @JAMACardio: This narrative review discusses drug-coated balloon angioplasty as an alternative to drug-eluting stent for percutaneous co….

🎄Made it to the @JAMACardio homepage! . Excited to share the latest review on #DCB in #CAD, co-led with @acamajmd. We focus on technologies, worldwide usage, indications and procedural aspects. 🔗 Contemporary #PCI can offer more than #DES alone!

What a Wednesday at @MonteHeart!. 🥇case of AltaValve in New York. 🥇case enrolled in TRINITY EFS study with Lux-Valve Plus. Fantastic to be part of this terrific Team.@azeemlatib @jgranadacrf @modine_thomas @EdwinHoMD @m_assafin Tadahisa Sugiura @AndreaScotti21 @MatteoSturlaM

RT @lvjulien_md: It was an honor and a privilege to be part of the excellent team performing the first Supira-supported high-risk PCI at @M….

RT @azeemlatib: Congrats to @MadayGonzalez7 for starting our RDN program and performing the 1st renal denervation @MontefioreNYC. Great to….